Bellini Duct Carcinoma of the Kidney

Miyamoto, Hiroshi; Kuwamitsu, Osamu; Moriyama, Masatoshi; Sakanishi, Seizou; Fujii, Hiroshi; Fukushima, S; Sano, Jinyu; Oaki, Yoshiharu

doi:10.1159/000282379

Cited by 9 publications

(7 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In diagnosis of CDC, it is important to distinguish between invasive papillary RCC and urothelial carcinoma. Positive immunohistochemical staining for distal tubules and collecting duct markers is helpful indiscrimination of CDC from the more commonly diagnosed clear cell RCC of proximal nephron origin [5]. CDC generally expresses broad spectrum keratins and high molecular weight (HMW) cytokeratin, which is expressed in the lower nephron and the urothelium.…”

Section: Introductionmentioning

confidence: 99%

Clinical Features and Treatment of Collecting Duct Carcinoma of the Kidney from the Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee

Kwon

Oh²,

Kim³

et al. 2014

Cancer Res Treat

View full text Add to dashboard Cite

PurposeCollecting duct carcinoma (CDC) of the kidney is an aggressive disease with a poor prognosis, accountings for less than 1% of all renal cancers. To date, no standard therapy for CDC has been established. The aim of this study is an investigation of clinicopathologic findings of CDC and correlation of the disease status with a prognosis.Materials and MethodsFrom 1996 to 2009, 35 patients with CDC were treated at eight medical centers. The diagnosis of CDC was made based on nephrectomy in 27 cases and renal biopsy in eight cases.ResultsMedian PFS and OS for all patients were 5.8 months (95% CI 3.5 to 9.2) and 54.4 months (95% CI 0 to 109.2), respectively. The OS of patients with Stages I-III was 69.9 months (95% CI 54.0 to 85.8), while that of patients with Stage IV was 8.6 months (95% CI 0 to 23.3), which showed a statistically significant difference (p=0.01). In addition, among patients with Stage IV, the OS of patients who received a palliative treatment (immunotherapy, chemotherapy, or targeted therapy) was 18.4 months, which was higher than the OS of patients without treatment of 4.5 months.ConclusionCDC is a highly aggressive form of renal cell carcinoma. Despite most of the treatments, PFS and OS were short, however, there were some long-term survivors, therefore, conduct of additional research on the predictive markers of the several clinical, pathological differences and their treatments will be necessary.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical Features and Treatment of Collecting Duct Carcinoma of the Kidney from the Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee

Kwon

Oh²,

Kim³

et al. 2014

Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…The tumor's positivity for high-molecular-weight keratins supports an origin from the distal nephron [7,10,22]. Thus, immunohistochemistry can provide further evidence of its originating from the collecting ducts and is helpful to establish the diagnosis.…”

Section: Discussionmentioning

confidence: 84%

“…Also prior immunohistochemical studies of usual RCC have shown expression of LMWCK, CK19, EMA, VIM, Leu-M1, lysozyme and sometimes PNA but not HMWCK and UEA-1 [8,9,22]. Positivity of HMWCK supports the diagnosis of the CDC since these antigens are normally expressed in the distal tubules and collecting ducts but not in the proximal tubular epithelium [7,10,22]. This immunohistochemical profile changes especially for sarcomatoid variants such as negativity or less positivity of HMWCK according to the nonsarcomatoid CDC [1,22].…”

Section: Discussionmentioning

confidence: 88%

“…Previous studies have suggested that it originates from the collecting ducts, this assumption was based on the renal medullary location of the tumor, the histologic resemblance of the tumor's cells to the lining cells of the collecting ducts and atypia of nearby ducts [4,6]. Besides, the immunocytochemical and ultrastructural features of this tumor have also been cited as evidence for an origin from the collecting ducts [1,[3][4][5][7][8][9][10]. In this article we present a case with typical microscopic, histochemical and immunohistochemical features of CDC with atypical gross features.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Collecting Duct Carcinoma

Tulunay

Küpeli²,

Okçu³

et al. 2001

Urol Int

View full text Add to dashboard Cite

Collecting duct carcinoma of the kidney is a rare variant of renal cell carcinoma. Hematuria is the most common presenting symptom. This tubulopapillary tumor arises from or differentiates forward to medullary collecting tubules. It is typically centered on the medulla of the kidney and extends into the cortex with a desmoplastic reaction. There are few reports documenting the clinical presentation and long-term prognosis. We describe a case of this uncommon tumor with clinical, histological and immunohistochemical features and review the literature.

show abstract

“…C D C frequently presents as a renal mass causing flank pain and hematuria (Dimopoulos et al, 1993). These lesions are often mistaken preoperatively for RCC or transitional cell carcinoma (TCC) of the renal pelvis and CDC frequently shows evidence of metastatic disease (Mancilla-Jimenez et al, 1976;Cromie et al, 1979;Aizawa et al, 1986;Fleming and Lewi, 1986;Kennedy et al, 1990;Rumpelt et al, 1991;Carter et al, 1992;Fuzesi et al, 1992;Miyamoto et al, 1992;Dimopoulos et al, 1993;Halenda et al, 1993). CDCs can be differentiated from RCC on the basis of a constellation of gross and microscopic features (Table 1).…”

mentioning

confidence: 99%

Frequent Loss of Chromosome Arms 8p and 13q in Collecting Duct Carcinoma (CDC) of the Kidney

Schoenberg

Brooks

Marshall

et al. 1995

Genes Chromosomes & Cancer

View full text Add to dashboard Cite

Collecting duct carcinoma (CDC) is a malignant renal neoplasm that is believed to arise from the epithelium of the ducts of Bellini in the distal nephron. These tumors are clinically aggressive and more often occur in a younger population than is typical of the more common clear cell renal carcinoma (RCC). Using highly informative polymorphic microsatellite markers on chromosome arms 3p, 5q, 6q, 9p, 9q, 11p, 13q, 17p, and 18q, we analyzed DNA from nonmalignant and tumor tissue in 6 cases of CDC. We found no evidence of 3p loss of heterozygosity (LOH) in these renal tumors by using multiple markers, a finding that distinguishes CDC from RCC in which 3p LOH has frequently been observed. We found LOH of 8p in 50% of the tumors examined; in addition, we observed LOH of 13q in 50% of the tumors studied. Interestingly, 8p LOH may be associated with high stage and poor clinical prognosis. These data suggest that the molecular events responsible for the development of CDC differ from those associated with the origin of RCC, and that tumor suppressor genes on 8p and 13q may be involved in the pathogenesis of CDC.

show abstract

Bellini Duct Carcinoma of the Kidney

Cited by 9 publications

References 4 publications

Clinical Features and Treatment of Collecting Duct Carcinoma of the Kidney from the Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee

Clinical Features and Treatment of Collecting Duct Carcinoma of the Kidney from the Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee

Collecting Duct Carcinoma

Frequent Loss of Chromosome Arms 8p and 13q in Collecting Duct Carcinoma (CDC) of the Kidney

Contact Info

Product

Resources

About